What exactly did Bank of America do on March 09, 2026 for Agilent (A)?

On March 09, 2026 Bank of America Securities reiterated a **Neutral** rating on Agilent (A) after the Biocare acquisition announcement. The note did not include a new price target and signaled the firm will monitor integration and execution before changing its view.

How should investors interpret a maintained Neutral A analyst rating?

A maintained Neutral indicates expectations that Agilent will perform roughly in line with peers over 6 to 12 months. It is neither a clear buy nor a sell. Investors should focus on upcoming results, integration milestones, and guidance revisions.

Did Bank of America set a new A price target with the update?

No. The StreetInsider report shows Bank of America reiterated the Neutral rating without issuing a new A price target. That omission means valuation guidance remains with the firm’s prior published view.

How does Meyka AI view Agilent after the maintained rating?

Meyka AI rates A with a grade of **A**. The grade combines S&P 500 comparison, sector performance, financial growth, key metrics, and analyst consensus. This is an informational score and not financial advice.

Analyst Ratings

Bank of America Maintains Neutral on Agilent Technologies (A) March 2026

ByHuzaifa Zahoor March 10, 2026March 10, 2026

On March 09, 2026 Bank of America Securities maintained a Neutral rating on Agilent Technologies, Inc. (A) following the company’s Biocare Medical acquisition announcement. The note kept coverage steady and did not issue a new price target.